TeamDrive
RUS
Leonid Melamed

Leonid Melamed

Founding Partner, Chairman of The Board of Directors

Телефоны:

+7 495 545-39-12

Send message

​Leonid has almost 30 years of management experience at large companies in various market sectors.

Leonid – one of the leader of the team, implementing a major pharmaceutical and medical project, the brainchild of its investors RUSNANO OJSC and the American firm Domain Associates LLC. RusnanoMedInvest LLC (RMI) was founded to implement this project. RMI is the largest venture capital company in life sciences in Eastern Europe, focusing on innovative pharmaceutical projects backed by sustainable, cutting edge technologies. Russian pharmaceutical company NovaMedica LLC is responsible for the localisation of the products and technologies in Russia. It was also founded to implement ambitious plans to create a new GMP-compliant production facility and facilitate the production of innovative drugs.

Leonid Melamed is the co-founder and Chairman of the Board of Directors of RMI Partners (venture capital investment company), which manages the healthcare projects, one of them - a venture capital fund RusnanoMedInvest (RMI). One of the main investment in the RMI portfolio is NovaMedica LLC. At the present time Leonid is a member of the Board of Directors of RusnanoMedInvest and from 2012 to 2017 he was a member of the Board of NovaMedica.

Leonid also is the co-founder and member of the Board of Directors of Doctor Ryadom (network of medical clinics), which among the first in Russia began to provide telemedicine services to its patients.

Earlier Leonid was the President and Chairman of the Management Board and member of the Board of Directors of Sistema JFSC (from 2008 to 2011). From 2006 to 2008, Leonid ran the telecommunications company Mobile TeleSystems (MTS OJSC) as President and Chairman of the Management Board. For 15 years from 1991 to 2006 Leonid participated in the creation and development of ROSNO insurance company. In 2003 he was the head of ROSNO as CEO and Chairman of the Management Board.

His personal “portfolio” includes Russneft OJSC as Chairman of the Board of Directors (2010-2012) and VTB OJSC as a member of the Supervisory Board (2012-2013).

Currently, Leonid is a member of the Government Expert Council of the Russian Federation, which was established to involve the business community in the preparation and implementation of the Government’s decisions.

Leonid graduated with honours from I.M. Sechenov Moscow Medical Academy and in 2006 became a Doctor of Medical Sciences.

Media Center

  • 23 November 2017

    Registration of medicines in EAEU will be performed online

    The Eurasian Economic Union (EAEU) is completing the development of a unified information system that will facilitate the registration of medicinal products by businesses in the common market and provide complete information about these drugs to consumers.

  • 23 November 2017

    Kaluga Pharmaceutical Cluster received silver certificate of Cluster Excellence

    In the period of October 24 – 26, 2017, the Association of Kaluga Pharmaceutical Cluster passed the procedure of the on-site audit conducted by the experts of the European Secretariat for Cluster Analysis. The procedure included the evaluation of the cluster management system and core activities  using 30 indicators in accordance with the methodology of the European Cluster Excellence Initiative. The assessment score of the Association of Kaluga Pharmaceutical Cluster performance for more than 70% of these indicators have significantly exceeded the required values. 

  • 22 November 2017

    After unexpected tie, Amsterdam wins ‘coin toss’ for new EMA HQ

    Well, that was unexpected. The EU’s third and final vote on the new location of the European Medicine Agency tied between Milan and Amsterdam, with Amsterdam winning the proverbial coin toss tie-breaker (EU officials drew the city’s name out of a bowl).

  • 22 November 2017

    With only 2 warnings in 2017, pharma's ad police hits historic low

    As the end of the year nears, the pharma industry can usually look back at FDA enforcement letters for insight into the agency's thinking and guidance on marketing communications. But this year, there’s not much to review.

Read more